Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Часто задаваемые вопросы
В каком секторе работает Amylyx Pharmaceuticals Inc. Common Stock (AMLX)?
Amylyx Pharmaceuticals Inc. Common Stock относится к сектору Здравоохранение.
Какова текущая цена акций Amylyx Pharmaceuticals Inc. Common Stock (AMLX)?
По последним данным, цена акций Amylyx Pharmaceuticals Inc. Common Stock составляет 23,63 $, предыдущее закрытие — 22,67 $. За последнюю торговую сессию акции Amylyx Pharmaceuticals Inc. Common Stock выросли на 0,96 $, что соответствует росту на 4,23%.
Выплачивает ли Amylyx Pharmaceuticals Inc. Common Stock (AMLX) дивиденды?
Нет, Amylyx Pharmaceuticals Inc. Common Stock не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Amylyx Pharmaceuticals Inc. Common Stock (AMLX)?
У компании Amylyx Pharmaceuticals Inc. Common Stock бета -0.205, что указывает на более низкую волатильность по сравнению с рынком в целом.
